Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Pembrolizumab vs IV Pembrolizumab in First-line Metastatic NSCLC (Japan Extension)
NCT06212752Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06212752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212752.